{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:29:20Z","timestamp":1786591760706,"version":"build-2736575974"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose of Review<\/jats:title>\n<jats:p>Cardiotoxicity by anticancer agents has emerged as a multifaceted issue and is expected to affect both mortality and morbidity. This review summarizes clinical challenges in the management of oncological patients requiring anticoagulants for atrial fibrillation (AF) also considering the current outbreak of the COVID-19 (coronavirus disease 2019) pandemic, since this infection can add challenges to the management of both conditions. Specifically, the aims are manyfold: (1) describe the evolving use of direct oral anticoagulants (DOACs) in AF patients with cancer; (2) critically appraise the risk of clinically important drug-drug interactions (DDIs) between DOACs and oral targeted anticancer agents; (3) address expected DDIs between DOACs and candidate anti-COVID drugs, with implications on management of the underlying thrombotic risk; and (4) characterize the proarrhythmic liability in cardio-oncology in the setting of COVID-19, focusing on QT prolongation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Recent Findings<\/jats:title>\n<jats:p>AF in cardio-oncology poses diagnostic and management challenges, also due to the number of anticancer drugs recently associated with AF onset\/worsening. Oral targeted drugs can potentially interact with DOACs, with increased bleeding risk mainly due to pharmacokinetic DDIs. Moreover, the vast majority of oral anticancer agents cause QT prolongation with direct and indirect mechanisms, potentially resulting in the occurrence of torsade de pointes, especially in susceptible patients with COVID-19 receiving additional drugs with QT liability.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Summary<\/jats:title>\n<jats:p>Oncologists and cardiologists must be aware of the increased bleeding risk and arrhythmic susceptibility of patients with AF and cancer due to DDIs. High-risk individuals with COVID-19 should be prioritized to target preventive strategies, including optimal antithrombotic management, medication review, and stringent monitoring.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s11897-020-00485-9","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T19:02:49Z","timestamp":1602010969000},"page":"365-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia"],"prefix":"10.1007","volume":"17","author":[{"given":"Milo","family":"Gatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Martignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Salvagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Diemberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"36","key":"485_CR1","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"\u2022\u2022 Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801 The first position paper on cardiovascular toxicities with anticancer drugs.","journal-title":"Eur Heart J"},{"issue":"4","key":"485_CR2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11739-018-1853-7","volume":"13","author":"E Raschi","year":"2018","unstructured":"Raschi E, Diemberger I, Cosmi B, De Ponti F. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors\u2019 reply. Intern Emerg Med. 2018;13(4):635\u20136.","journal-title":"Intern Emerg Med"},{"issue":"2","key":"485_CR3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pharmthera.2009.10.002","volume":"125","author":"E Raschi","year":"2010","unstructured":"Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, De Ponti F. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther. 2010;125(2):196\u2013218.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"485_CR4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11739-011-0744-y","volume":"7","author":"E Raschi","year":"2012","unstructured":"Raschi E, De Ponti F. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med. 2012;7(2):113\u201331.","journal-title":"Intern Emerg Med"},{"key":"485_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17:474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1.","journal-title":"Nat Rev Cardiol"},{"key":"485_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17:503\u201322. https:\/\/doi.org\/10.1038\/s41569-020-0347-2.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"485_CR7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ehjqcco\/qcx004","volume":"3","author":"C Melloni","year":"2017","unstructured":"Melloni C, Shrader P, Carver J, Piccini JP, Thomas L, Fonarow GC, et al. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017;3(3):192\u20137.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"8","key":"485_CR8","doi-asserted-by":"crossref","first-page":"e102861","DOI":"10.1371\/journal.pone.0102861","volume":"9","author":"EB Ostenfeld","year":"2014","unstructured":"Ostenfeld EB, Erichsen R, Pedersen L, Farkas DK, Weiss NS, S\u00f8rensen HT. Atrial fibrillation as a marker of occult cancer. PLoS One. 2014;9(8):e102861.","journal-title":"PLoS One"},{"issue":"2","key":"485_CR9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","volume":"165","author":"YF Hu","year":"2013","unstructured":"Hu YF, Liu CJ, Chang PM, Tsao HM, Lin YJ, Chang SL, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol. 2013;165(2):355\u20137.","journal-title":"Int J Cardiol"},{"issue":"4","key":"485_CR10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jamacardio.2016.0280","volume":"1","author":"D Conen","year":"2016","unstructured":"Conen D, Wong JA, Sandhu RK, Cook NR, Lee I-M, Buring JE, et al. Risk of malignant cancer among women with new-onset atrial fibrillation. JAMA Cardiol. 2016;1(4):389\u201396.","journal-title":"JAMA Cardiol"},{"issue":"12","key":"485_CR11","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","volume":"130","author":"C Melloni","year":"2017","unstructured":"Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med. 2017;130(12):1440\u20131448.e1.","journal-title":"Am J Med"},{"issue":"2","key":"485_CR12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","volume":"5","author":"ST Chen","year":"2019","unstructured":"Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes. 2019;5(2):145\u201352.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"16","key":"485_CR13","doi-asserted-by":"crossref","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","volume":"7","author":"CL Fanola","year":"2018","unstructured":"Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial. J Am Heart Assoc. 2018;7(16):e008987.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"485_CR14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","volume":"25","author":"M D\u2019Souza","year":"2018","unstructured":"D\u2019Souza M, Carlson N, Fosb\u00f8l E, Lamberts M, Smedegaard L, Nielsen D, et al. CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol. 2018;25(6):651\u20138.","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"485_CR15","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.amjcard.2017.08.038","volume":"120","author":"R Patell","year":"2017","unstructured":"Patell R, Gutierrez A, Rybicki L, Khorana AA. Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation. Am J Cardiol. 2017;120(12):2182\u20136.","journal-title":"Am J Cardiol"},{"issue":"2","key":"485_CR16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146\u201353.","journal-title":"N Engl J Med"},{"issue":"16","key":"485_CR17","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"\u2022\u2022 Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u201393 The updated EHRA guideline specifically devoted to the use of DOACs, including the issue of drug interactions.","journal-title":"Eur Heart J"},{"issue":"6","key":"485_CR18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"V Launay-Vacher","year":"2007","unstructured":"Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376\u201384.","journal-title":"Cancer."},{"issue":"1","key":"485_CR19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10157-017-1448-z","volume":"22","author":"S Horie","year":"2018","unstructured":"Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, et al. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol. 2018;22(1):210\u201344.","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"485_CR20","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","volume":"103","author":"N Janus","year":"2010","unstructured":"Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815\u201321.","journal-title":"Br J Cancer"},{"key":"485_CR21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2017.03.132","volume":"240","author":"B Mery","year":"2017","unstructured":"Mery B, Guichard JB, Guy JB, Vallard A, Barthelemy JC, Da Costa A, et al. Atrial fibrillation in cancer patients: hindsight, insight and foresight. Int J Cardiol. 2017;240:196\u2013202.","journal-title":"Int J Cardiol"},{"key":"485_CR22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","volume":"135","author":"P Gelosa","year":"2018","unstructured":"Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res. 2018;135:60\u201379.","journal-title":"Pharmacol Res"},{"issue":"12","key":"485_CR23","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s40264-019-00866-7","volume":"42","author":"E Raschi","year":"2019","unstructured":"Raschi E, Bianchin M, Gatti M, Squizzato A, De Ponti F. Comparative effectiveness and safety of direct oral anticoagulants: overview of systematic reviews. Drug Saf. 2019;42(12):1409\u201322.","journal-title":"Drug Saf"},{"issue":"2","key":"485_CR24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40264-018-0778-4","volume":"42","author":"G Curigliano","year":"2019","unstructured":"Curigliano G, Shah RR. Safety and tolerability of phosphatidylinositol-3-kinase (PI3K) inhibitors in oncology. Drug Saf. 2019;42(2):247\u201362.","journal-title":"Drug Saf"},{"key":"485_CR25","doi-asserted-by":"crossref","first-page":"175883591983386","DOI":"10.1177\/1758835919833867","volume":"11","author":"M Bellet","year":"2019","unstructured":"Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019;11:1758835919833867.","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"485_CR26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JOP.2017.022004","volume":"13","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Daughety MM, Olson SR, Beer TM, DeLoughery TG. Management of anticoagulation in patients with prostate cancer receiving enzalutamide. J Oncol Pract. 2017;13(11):720\u20137.","journal-title":"J Oncol Pract"},{"key":"485_CR27","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2147\/OTT.S130990","volume":"10","author":"Y Peng","year":"2017","unstructured":"Peng Y, Cui H, Liu Z, Liu D, Liu F, Song Y, et al. Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. Onco Targets Ther. 2017;10:2289\u201395.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"485_CR28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00228-016-2115-0","volume":"73","author":"PH Hsyu","year":"2017","unstructured":"Hsyu PH, Pignataro DS, Matschke K. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. Eur J Clin Pharmacol. 2017;73(1):57\u201363.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"485_CR29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hon.2545","volume":"36","author":"A Visentin","year":"2018","unstructured":"Visentin A, Campello E, Scomazzon E, Spiezia L, Imbergamo S, Pravato S, et al. Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: experience of 4 cases. Hematol Oncol. 2018;36(5):801\u20133.","journal-title":"Hematol Oncol"},{"issue":"1","key":"485_CR30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40520-017-0752-5","volume":"30","author":"R Quintavalla","year":"2018","unstructured":"Quintavalla R, Lombardi M, Prandoni P, Manotti C, Tadonio I, Re F, et al. Increased dabigatran plasma concentration during ibrutinib treatment: a case of cerebral hemorrhage and successful dabigatran reversal by idarucizumab. Aging Clin Exp Res. 2018;30(1):93\u20135.","journal-title":"Aging Clin Exp Res"},{"key":"485_CR31","doi-asserted-by":"publisher","unstructured":"Lewicka E, Daniluk P, Lasocka Z, Zarzycka E, D\u0105browska-Kugacka A, Nabia\u0142ek-Trojanowska I, et al. Assessment of dabigatran plasma concentrations may improve the safety of anticoagulation in patients with atrial fibrillation undergoing ibrutinib treatment. Kardiol Pol. 2020. https:\/\/doi.org\/10.33963\/KP.15255.","DOI":"10.33963\/KP.15255"},{"issue":"5","key":"485_CR32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ccr3.2106","volume":"7","author":"MMA Waite","year":"2019","unstructured":"Waite MMA, Martinelli AW, Preston SD, Gudgin E, Symington E, Rintoul RC, et al. A hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinoma. Clin Case Rep. 2019;7(5):888\u201392.","journal-title":"Clin Case Rep"},{"issue":"2","key":"485_CR33","first-page":"ytx018","volume":"1","author":"T Nassif","year":"2017","unstructured":"Nassif T, Banchs J, Yusuf SW, Mouhayar E. Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series. Eur Heart J Case Rep. 2017;1(2):ytx018.","journal-title":"Eur Heart J Case Rep"},{"issue":"6","key":"485_CR34","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1097\/MJT.0000000000000775","volume":"25","author":"M Khalid","year":"2018","unstructured":"Khalid M, Khattak F, Ramu V. Cardiovascular side effects of tyrosine kinase inhibitor ibrutinib (imbruvica) and interaction with direct oral anticoagulant. Am J Ther. 2018;25(6):e768\u20139.","journal-title":"Am J Ther"},{"issue":"5","key":"485_CR35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.annder.2016.09.681","volume":"144","author":"A Le Guern","year":"2017","unstructured":"Le Guern A, Lebas D, Thillard EM, Martincic C, Wiart T, Modiano P. Hemorrhagic syndrome during cobimetinib therapy: the need for caution in patients receiving new anticoagulant drugs. Ann Dermatol Venereol. 2017;144(5):383\u20134.","journal-title":"Ann Dermatol Venereol"},{"key":"485_CR36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40164-019-0146-9","volume":"8","author":"D Santini","year":"2019","unstructured":"Santini D, Citarella F, Vincenzi B, Russano M, Tonini G, Stellato M. Cabozantinib and apixaban: an hitherto unreported interaction. Exp Hematol Oncol. 2019;8:22.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"485_CR37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40264-017-0529-y","volume":"40","author":"E Poluzzi","year":"2017","unstructured":"Poluzzi E, Raschi E, Diemberger I, De Ponti F. Drug-induced arrhythmia: bridging the gap between pathophysiological knowledge and clinical practice. Drug Saf. 2017;40(6):461\u20134.","journal-title":"Drug Saf"},{"issue":"4","key":"485_CR38","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844\u20137.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"485_CR39","doi-asserted-by":"crossref","first-page":"ofaa105","DOI":"10.1093\/ofid\/ofaa105","volume":"7","author":"EK McCreary","year":"2020","unstructured":"McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020;7(4):ofaa105.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"485_CR40","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00228-016-2107-0","volume":"72","author":"B Clarivet","year":"2016","unstructured":"Clarivet B, Robin P, Pers YM, Ferreira R, Lebrun J, Jorgensen C, et al. Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and\/or by P-glycoprotein. Eur J Clin Pharmacol. 2016;72(11):1413\u20134.","journal-title":"Eur J Clin Pharmacol"},{"key":"485_CR41","first-page":"w13906","volume":"144","author":"B Lakatos","year":"2014","unstructured":"Lakatos B, Stoeckle M, Elzi L, Battegay M, Marzolini C. Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. Swiss Med Wkly. 2014;144:w13906.","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"485_CR42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40800-015-0014-4","volume":"2","author":"CE Corallo","year":"2015","unstructured":"Corallo CE, Grannell L, Tran H. Postoperative bleeding after administration of a single dose of rivaroxaban to a patient receiving antiretroviral therapy. Drug Saf Case Rep. 2015;2(1):11.","journal-title":"Drug Saf Case Rep"},{"issue":"3","key":"485_CR43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","volume":"76","author":"W Mueck","year":"2013","unstructured":"Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455\u201366.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 2","key":"485_CR44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00059-014-4188-9","volume":"40","author":"C St\u00f6llberger","year":"2015","unstructured":"St\u00f6llberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015;40(Suppl 2):140\u20135.","journal-title":"Herz."},{"issue":"7","key":"485_CR45","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1177\/0956462419832099","volume":"30","author":"SA Nisly","year":"2019","unstructured":"Nisly SA, Stevens BN. Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: a case for apixaban. Int J STD AIDS. 2019;30(7):718\u201322.","journal-title":"Int J STD AIDS"},{"issue":"11","key":"485_CR46","doi-asserted-by":"crossref","first-page":"e01201","DOI":"10.1128\/AAC.01201-17","volume":"61","author":"P Kumar","year":"2017","unstructured":"Kumar P, Gordon LA, Brooks KM, George JM, Kellogg A, McManus M, et al. Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic\/pharmacodynamic disposition of dabigatran. Antimicrob Agents Chemother. 2017;61(11):e01201\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"485_CR47","unstructured":"George JM, Kuriakose SS, Monroe A, Hou Q, Byrne M, Pau AK, et al. Utilization of direct oral anticoagulants in people with HIV: observational data from the DC cohort. Clin Infect Dis. 2020:ciaa284."},{"key":"485_CR48","doi-asserted-by":"crossref","unstructured":"Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020:105954.","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"issue":"2","key":"485_CR49","first-page":"143","volume":"28","author":"Lombardy Section Italian Society Infectious And Tropical Diseases","year":"2020","unstructured":"Lombardy Section Italian Society Infectious And Tropical Diseases. Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020. Infez Med. 2020;28(2):143\u201352.","journal-title":"Infez Med"},{"issue":"13","key":"485_CR50","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1096\/fj.02-0195fje","volume":"16","author":"R Jover","year":"2002","unstructured":"Jover R, Bort R, G\u00f3mez-Lech\u00f3n MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 2002;16(13):1799\u2013801.","journal-title":"FASEB J"},{"issue":"6","key":"485_CR51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40262-016-0462-8","volume":"56","author":"EB Lee","year":"2017","unstructured":"Lee EB, Daskalakis N, Xu C, Paccaly A, Miller B, Fleischmann R, et al. Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacokinet. 2017;56(6):607\u201315.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"485_CR52","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735\u201340.","journal-title":"Clin Pharmacol Ther"},{"key":"485_CR53","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/jth.14871","volume":"18","author":"S Testa","year":"2020","unstructured":"Testa S, Prandoni P, Paoletti O, Morandini R, Tala M, Dellanoce C, et al. Direct oral anticoagulant plasma levels\u2019 striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost. 2020;18:1320\u20133. https:\/\/doi.org\/10.1111\/jth.14871.","journal-title":"J Thromb Haemost"},{"key":"485_CR54","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s11739-020-02331-1","volume":"15","author":"S Testa","year":"2020","unstructured":"Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med. 2020;15:751\u20133. https:\/\/doi.org\/10.1007\/s11739-020-02331-1.","journal-title":"Intern Emerg Med"},{"key":"485_CR55","unstructured":"\u2022\u2022 Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;(20):35008\u20137 The first comprehensive assessment of thrombotic issues in COVID-19."},{"issue":"2","key":"485_CR56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","volume":"38","author":"J Tamargo","year":"2015","unstructured":"Tamargo J, Caballero R, Delp\u00f3n E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015;38(2):129\u201352.","journal-title":"Drug Saf"},{"issue":"10","key":"485_CR57","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","volume":"63","author":"D Farmakis","year":"2014","unstructured":"Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63(10):945\u201353.","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"485_CR58","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1093\/eurheartj\/ehz649","volume":"40","author":"A Guha","year":"2019","unstructured":"Guha A, Dey AK, Jneid H, Ibarz JP, Addison D, Fradley M. Atrial fibrillation in the era of emerging cancer therapies. Eur Heart J. 2019;40(36):3007\u201310.","journal-title":"Eur Heart J"},{"key":"485_CR59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","volume":"189","author":"J Alexandre","year":"2018","unstructured":"Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018;189:89\u2013103.","journal-title":"Pharmacol Ther"},{"key":"485_CR60","doi-asserted-by":"publisher","unstructured":"Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identification of anticancer drugs associated with atrial fibrillation - analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2020:pvaa037. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa037.","DOI":"10.1093\/ehjcvp\/pvaa037"},{"issue":"4","key":"485_CR61","doi-asserted-by":"publisher","first-page":"e0122646","DOI":"10.1371\/journal.pone.0122646","volume":"10","author":"DH Kim","year":"2015","unstructured":"Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015;10(4):e0122646. https:\/\/doi.org\/10.1371\/journal.pone.0122646 eCollection 2015.","journal-title":"PLoS One"},{"issue":"4","key":"485_CR62","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0038-1648229","volume":"44","author":"A Tufano","year":"2018","unstructured":"Tufano A, Galderisi M, Esposito L, Trimarco V, Sorriento D, Gerusalem G, et al. Anticancer drug-related nonvalvular atrial fibrillation: challenges in management and antithrombotic strategies. Semin Thromb Hemost. 2018;44(4):388\u201396.","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"485_CR63","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"485_CR64","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14740338.2012.698609","volume":"11","author":"J Tamargo","year":"2012","unstructured":"Tamargo J, Caballero R, Delp\u00f3n E. Drug-induced atrial fibrillation. Expert Opin Drug Saf. 2012;11(4):615\u201334.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"485_CR65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","volume":"378","author":"NF Marrouche","year":"2018","unstructured":"Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417\u201327.","journal-title":"N Engl J Med"},{"issue":"15","key":"485_CR66","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.0000058706.82623.A1","volume":"107","author":"P Khairy","year":"2003","unstructured":"Khairy P, Chauvet P, Lehmann J, Lambert J, Macle L, Tanguay JF, et al. Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation. Circulation. 2003;107(15):2045\u201350.","journal-title":"Circulation."},{"key":"485_CR67","doi-asserted-by":"publisher","unstructured":"Giustozzi M, Ali H, Reboldi G, Balla C, Foresti S, de Ambroggi G, et al. Safety of catheter ablation of atrial fibrillation in cancer survivors. J Interv Card Electrophysiol. 2020. https:\/\/doi.org\/10.1007\/s10840-020-00745-7.","DOI":"10.1007\/s10840-020-00745-7"},{"issue":"12","key":"485_CR68","doi-asserted-by":"crossref","first-page":"120702","DOI":"10.1118\/1.4901414","volume":"41","author":"S Ipsen","year":"2014","unstructured":"Ipsen S, Blanck O, Oborn B, Bode F, Liney G, Hunold P, et al. Radiotherapy beyond cancer: target localization in real-time MRI and treatment planning for cardiac radiosurgery. Med Phys. 2014;41(12):120702.","journal-title":"Med Phys"},{"issue":"7","key":"485_CR69","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615\u201324.","journal-title":"N Engl J Med"},{"issue":"3","key":"485_CR70","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40264-013-0016-z","volume":"36","author":"N Stockbridge","year":"2013","unstructured":"Stockbridge N, Morganroth J, Shah RR, Garnett C. Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf. 2013;36(3):167\u201382.","journal-title":"Drug Saf"},{"issue":"10","key":"485_CR71","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40261-017-0563-7","volume":"37","author":"I Diemberger","year":"2017","unstructured":"Diemberger I, Raschi E, Trifir\u00f2 G. Balancing the need for personalization of QT correction and generalization of study results: going beyond thorough QT studies. Clin Drug Investig. 2017;37(10):985\u20138.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"485_CR72","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tcm.2017.07.010","volume":"28","author":"RL Woosley","year":"2018","unstructured":"Woosley RL, Black K, Heise CW, Romero K. CredibleMeds.org: what does it offer? Trends Cardiovasc Med. 2018;28(2):94\u20139.","journal-title":"Trends Cardiovasc Med"},{"issue":"5","key":"485_CR73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295\u2013316.","journal-title":"Drug Saf"},{"issue":"8","key":"485_CR74","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","volume":"38","author":"RR Shah","year":"2015","unstructured":"Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit. Drug Saf. 2015;38(8):693\u2013710.","journal-title":"Drug Saf"},{"issue":"1","key":"485_CR75","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12885-020-06855-9","volume":"20","author":"M Ismail","year":"2020","unstructured":"Ismail M, Khan S, Khan F, Noor S, Sajid H, Yar S, et al. Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer. 2020;20(1):335.","journal-title":"BMC Cancer"},{"key":"485_CR76","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1007\/s00520-019-05204-2","volume":"28","author":"SH Kim","year":"2019","unstructured":"Kim SH, Suh Y, Ah YM, Jun K, Lee JY. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study. Support Care Cancer. 2019;28:3617\u201326. https:\/\/doi.org\/10.1007\/s00520-019-05204-2.","journal-title":"Support Care Cancer"},{"issue":"3","key":"485_CR77","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.phrs.2008.01.009","volume":"57","author":"E Raschi","year":"2008","unstructured":"Raschi E, Vasina V, Poluzzi E, De Ponti F. The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res. 2008;57(3):181\u201395.","journal-title":"Pharmacol Res"},{"issue":"3","key":"485_CR78","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/jpet.117.246157","volume":"365","author":"T Yang","year":"2018","unstructured":"Yang T, Meoli DF, Moslehi J, Roden DM. Inhibition of the \u03b1-subunit of phosphoinositide 3-kinase in heart increases late sodium current and is arrhythmogenic. J Pharmacol Exp Ther. 2018;365(3):460\u20136.","journal-title":"J Pharmacol Exp Ther"},{"issue":"131","key":"485_CR79","first-page":"131ra50","volume":"4","author":"Z Lu","year":"2012","unstructured":"Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med. 2012;4(131):131ra50.","journal-title":"Sci Transl Med"},{"issue":"5","key":"485_CR80","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cvr\/cvz013","volume":"115","author":"DM Roden","year":"2019","unstructured":"\u2022 Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895\u2013903 An updated review on mechanisms and implications of drug-induced QT prolongation by anticancer agents.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"485_CR81","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/toxsci\/kfw104","volume":"153","author":"S Spence","year":"2016","unstructured":"Spence S, Deurinck M, Ju H, Traebert M, McLean L, Marlowe J, et al. Histone deacetylase inhibitors prolong cardiac repolarization through transcriptional mechanisms. Toxicol Sci. 2016;153(1):39\u201354.","journal-title":"Toxicol Sci"},{"key":"485_CR82","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.yjmcc.2018.01.009","volume":"115","author":"P Li","year":"2018","unstructured":"Li P, Kurata Y, Endang M, Ninomiya H, Higaki K, Taufiq F, et al. Restoration of mutant hERG stability by inhibition of HDAC6. J Mol Cell Cardiol. 2018;115:158\u201369.","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"485_CR83","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 2019;42(2):181\u201398.","journal-title":"Drug Saf"},{"issue":"2","key":"485_CR84","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40264-018-0771-y","volume":"42","author":"D Rocco","year":"2019","unstructured":"Rocco D, Battiloro C, Della Gravara L, Gridelli C. Safety and tolerability of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Drug Saf. 2019;42(2):199\u2013209.","journal-title":"Drug Saf"},{"issue":"2","key":"485_CR85","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","volume":"42","author":"A Puccini","year":"2019","unstructured":"Puccini A, Mar\u00edn-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz HJ, et al. Safety and tolerability of c-MET inhibitors in cancer. Drug Saf. 2019;42(2):211\u201333.","journal-title":"Drug Saf"},{"issue":"2","key":"485_CR86","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah RR. Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf. 2019;42(2):235\u201345.","journal-title":"Drug Saf"},{"issue":"10","key":"485_CR87","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","volume":"102","author":"I de Weerdt","year":"2017","unstructured":"de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629\u201339.","journal-title":"Haematologica."},{"issue":"2","key":"485_CR88","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40264-018-0777-5","volume":"42","author":"RL Carpenter","year":"2019","unstructured":"Carpenter RL, Ray H. Safety and tolerability of sonic hedgehog pathway inhibitors in cancer. Drug Saf. 2019;42(2):263\u201379.","journal-title":"Drug Saf"},{"issue":"21","key":"485_CR89","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1136\/heartjnl-2018-314674","volume":"105","author":"RC Pezo","year":"2019","unstructured":"Pezo RC, Yan AT, Earle C, Chan KK. Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. Heart. 2019;105(21):1649\u201355.","journal-title":"Heart."},{"issue":"8","key":"485_CR90","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00228-015-1874-3","volume":"71","author":"I Diemberger","year":"2015","unstructured":"Diemberger I, Massaro G, Cubelli M, Rubino D, Quercia S, Martignani C, et al. Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs. Eur J Clin Pharmacol. 2015;71(8):1001\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"485_CR91","doi-asserted-by":"publisher","unstructured":"Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020:cvaa106. https:\/\/doi.org\/10.1093\/cvr\/cvaa106.","DOI":"10.1093\/cvr\/cvaa106"},{"key":"485_CR92","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1161\/CIRCULATIONAHA.120.047349","volume":"141","author":"NS Hendren","year":"2020","unstructured":"Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020;141:1903\u201314. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047349.","journal-title":"Circulation."},{"key":"485_CR93","doi-asserted-by":"publisher","unstructured":"Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation. 2020. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047293.","DOI":"10.1161\/CIRCULATIONAHA.120.047293"},{"issue":"10","key":"485_CR94","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.hrthm.2015.05.027","volume":"12","author":"RA Capel","year":"2015","unstructured":"Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: novel electrophysiological insights and therapeutic potential. Heart Rhythm. 2015;12(10):2186\u201394.","journal-title":"Heart Rhythm"},{"key":"485_CR95","doi-asserted-by":"crossref","unstructured":"Gollob MH. COVID-19, clinical trials and QT-prolonging prophylactic therapy in healthy subjects: first, do no harm. J Am Coll Cardiol. 2020;(20):35228\u20131.","DOI":"10.1016\/j.jacc.2020.05.008"},{"issue":"18","key":"485_CR96","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","volume":"75","author":"E Driggin","year":"2020","unstructured":"Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"485_CR97","doi-asserted-by":"crossref","first-page":"E560","DOI":"10.1503\/cmaj.160355","volume":"189","author":"G Trifir\u00f2","year":"2017","unstructured":"Trifir\u00f2 G, de Ridder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, et al. Use of azithromycin and risk of ventricular arrhythmia. CMAJ. 2017;189(15):E560\u20138.","journal-title":"CMAJ."},{"issue":"1","key":"485_CR98","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41577-018-0098-z","volume":"19","author":"PE Lazzerini","year":"2019","unstructured":"Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019;19(1):63\u20134.","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"485_CR99","first-page":"1717","volume":"38","author":"PE Lazzerini","year":"2017","unstructured":"Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2017;38(22):1717\u201327.","journal-title":"Eur Heart J"},{"issue":"3","key":"485_CR100","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/acr.22455","volume":"67","author":"PE Lazzerini","year":"2015","unstructured":"Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, et al. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res. 2015;67(3):332\u20139.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"485_CR101","doi-asserted-by":"crossref","first-page":"106","DOI":"10.15420\/cfr.2019.1.2","volume":"5","author":"E Bertero","year":"2019","unstructured":"Bertero E, Ameri P, Maack C. Bidirectional relationship between cancer and heart failure: old and new issues in cardio-oncology. Card Fail Rev. 2019;5(2):106\u201311.","journal-title":"Card Fail Rev"},{"issue":"5","key":"485_CR102","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.hrthm.2017.01.027","volume":"14","author":"NM De Jesus","year":"2017","unstructured":"De Jesus NM, Wang L, Lai J, Rigor RR, Francis Stuart SD, Bers DM, et al. Antiarrhythmic effects of interleukin 1 inhibition after myocardial infarction. Heart Rhythm. 2017;14(5):727\u201336.","journal-title":"Heart Rhythm"},{"issue":"8","key":"485_CR103","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11886-018-1007-6","volume":"20","author":"G Emmi","year":"2018","unstructured":"Emmi G, Urban ML, Imazio M, Gattorno M, Maestroni S, Lopalco G, et al. Use of interleukin-1 blockers in pericardial and cardiovascular diseases. Curr Cardiol Rep. 2018;20(8):61.","journal-title":"Curr Cardiol Rep"},{"key":"485_CR104","doi-asserted-by":"publisher","unstructured":"Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm Society. Can J Cardiol. 2020;(20):30325\u20131. https:\/\/doi.org\/10.1016\/j.cjca.2020.04.003.","DOI":"10.1016\/j.cjca.2020.04.003"},{"key":"485_CR105","doi-asserted-by":"publisher","unstructured":"Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020:2048872620922784\u2013221. https:\/\/doi.org\/10.1177\/2048872620922784.","DOI":"10.1177\/2048872620922784"},{"key":"485_CR106","doi-asserted-by":"publisher","unstructured":"Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020;(20):30313\u2013X. https:\/\/doi.org\/10.1016\/j.mayocp.2020.03.024.","DOI":"10.1016\/j.mayocp.2020.03.024"},{"key":"485_CR107","doi-asserted-by":"publisher","unstructured":"Sacher F, Fauchier L, Boveda S, de Chillou C, Defaye P, Deharo JC, et al. Electrophysiology of the French Society of Cardiology, the Board of the French Society of Cardiology. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection. Arch Cardiovasc Dis. 2020;(20):30100\u20135. https:\/\/doi.org\/10.1016\/j.acvd.2020.04.003.","DOI":"10.1016\/j.acvd.2020.04.003"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-020-00485-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-020-00485-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-020-00485-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T07:16:22Z","timestamp":1633504582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-020-00485-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["485"],"URL":"https:\/\/doi.org\/10.1007\/s11897-020-00485-9","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"6 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"AA reports fees for advisory board participation from Roche, Merck Sharp & Dohme, AstraZeneca, and Bristol Myers Squibb and research grants for spontaneous studies from Roche and Bristol Myers Squibb, all outside the scope of the present paper. ER reports personal fee from Novartis, outside the submitted work. ID reports minor speaker fees from Daiichi Sankyo, Boehringer Ingelheim, Pfizer, and Bayer, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Not available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}